Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
0.6199
+0.0341 (5.82%)
At close: Apr 28, 2025, 4:00 PM
0.6262
+0.0063 (1.02%)
Pre-market: Apr 29, 2025, 7:31 AM EDT
Adicet Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
152
Market Cap
51.26M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
ACET News
- 15 hours ago - Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - Business Wire
- 12 days ago - Adicet Bio Appoints Michael Grissinger to the Board of Directors - Business Wire
- 4 weeks ago - Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference - Business Wire
- 7 weeks ago - Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress - Business Wire
- 2 months ago - Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting - Business Wire
- 2 months ago - Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) - Business Wire
- 2 months ago - Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement - Business Wire